Recent Clinical Development & Regulatory Highlights:
- Completed FDA End of Review meeting for Apadaz™ following receipt of Complete Response Letter
- Reported results from KP511 Phase 1 Proof-of-Concept Trial; Announces plans to initiate human abuse liability program for
KP511 before year-end
- Completed key FDA regulatory milestones for KP415 and KP201/IR
Recent Corporate and Financial Highlights:
- Hosted annual meeting of stockholders on May 24th
- Total cash and cash equivalents, restricted cash, marketable securities and long-term investments of $102.6 million at June
30, 2016
- Net income of $9.8 million, or $0.59 per basic share, and ($0.58) net loss per diluted share for the quarter ended June 30,
2016
- Operating loss of $9.3 million for the quarter ended June 30, 2016
CORALVILLE, Iowa, Aug. 10, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical
company engaged in the discovery and development of proprietary prodrugs, today reported its corporate and financial results for
the second quarter ended June 30, 2016, including an update on key regulatory and clinical events involving KemPharm’s product
candidate Apadaz™ and KemPharm’s pipeline of other proprietary prodrugs.
On June 13, 2016, KemPharm announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL)
regarding the New Drug Application (NDA) for Apadaz (benzhydrocodone and acetaminophen), the Company’s investigational
abuse-deterrent product candidate for the short term management of acute pain. KemPharm subsequently requested an End of
Review meeting with the FDA, which occurred on August 3, 2016.
At the End-of-Review (EOR) meeting, the Company and the FDA discussed the issues identified by the FDA in the Apadaz NDA and
what KemPharm believes is the potential to achieve a path forward for an Apadaz product label that could include abuse deterrence
claims. The meeting also involved discussions pertaining to abuse deterrence in relation to the broader immediate-release
(IR) prescription opioid market, hydrocodone-acetaminophen combination products, and published industry guidance from the FDA
concerning the evaluation and labeling of abuse deterrent opioids.
The Company and the FDA also discussed the proposed short-duration “blister” packaging for Apadaz at the EOR meeting, which was
put forth as part of KemPharm’s Major Amendment Request to the Apadaz NDA prior to the June 9, 2016 PDUFA date. The Company
confirmed the information expected for the FDA to complete its review of the amendment. The short duration blister packaging
was proposed in alignment with the recently published Centers for Disease Control and Prevention’s Guideline for Prescribing
Opioids for Chronic Pain, which advises that clinicians should prescribe the lowest effective dose of immediate-release opioids and
should prescribe no greater quantity than needed for the expected duration of pain severe enough to require opioids.
“KemPharm’s mission today is unchanged – to leverage our unique and highly differentiated Ligand Activated Therapy (LAT)
discovery platform to develop proprietary prodrugs that have improved properties over currently approved drugs and address
significant medical needs in large, established markets,” said Travis C. Mickle, Ph.D., President and Chief Executive Officer of
KemPharm. “While the ongoing effort with the FDA concerning Apadaz has presented a near-term challenge for the company to work
through, we view it as a single event against multiple potential new product opportunities that hold considerable promise for
KemPharm. Our broad pipeline allows us to move forward with the development of our two most advanced extended-release product
candidates – KP511/ER for the treatment of severe pain and KP415 for the treatment of attention deficit hyperactivity disorder – as
well as with KP201/IR, our acetaminophen-free immediate release hydrocodone prodrug.”
Dr. Mickle concluded, “Looking ahead, we anticipate initiating the human abuse liability clinical program for KP511/ER and
filing Investigational New Drug (IND) applications for KP415 and KP201/IR by year-end. These programs represent the most immediate
value-building opportunities for KemPharm, and we are orienting our financial and R&D resources to support their potential for
success. Overall, we believe KemPharm remains well capitalized to advance its full pipeline of product candidates, while we
determine the optimal path forward for Apadaz.”
Ligand Activated Therapy (LAT) Prodrug Pipeline Update:
During the second quarter and early third quarter 2016, KemPharm achieved key clinical and regulatory milestones for KP511/ER,
KP415 and KP201/IR. Each of these prodrugs is based on KemPharm’s proprietary LAT discovery platform and is designed to
improve one or more of the attributes of the approved comparator drug, such as susceptibility to abuse, bioavailability and
safety.
On June 28, 2016, KemPharm reported positive results from its Phase 1 proof-of-concept trial of KP511, the Company’s prodrug of
hydromorphone. In the trial (KP511.101), KemPharm observed comparable hydromorphone exposure between 4 mg Dilaudid™ Oral
Liquid and an equimolar 8 mg dose of KP511. KemPharm is developing KP511 as an abuse-deterrent, extended release (ER) formulation
(KP511/ER) for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which
alternative treatments are inadequate. Based on these Phase 1 results, KemPharm plans to initiate a human abuse liability
clinical program for KP511/ER to assess the product candidate’s tamper and extraction resistance, its intranasal and intravenous
abuse potential, as well as its potential to limit oral abuse and/or overdose. Additionally, KemPharm intends to investigate
KP511’s potential to improve or reduce opioid-induced constipation (OIC), a common side effect of opioid therapy. KemPharm
anticipates initiating the KP511/ER human abuse liability program prior to the end of 2016.
On July 14, 2016, KemPharm announced the completion of a Pre-Investigational New Drug (Pre-IND) review of KP415, the Company’s
prodrug of d-threo-methylphenidate for the treatment of attention deficit hyperactivity disorder (ADHD). Based on input
received from the FDA, KemPharm expects to file an IND for KP415 before the end of 2016.
In preclinical studies of KP415, KemPharm observed features that it believes could provide significant benefits when compared
with other FDA-approved and widely prescribed methylphenidate products. Pharmacokinetic data from preclinical studies suggest that
the time to maximum plasma concentration of methylphenidate after oral administration of KP415 is approximately three times longer
compared to currently marketed IR methylphenidate. KemPharm believes this potential controlled release attribute of KP415’s
molecular structure may allow for convenient, once-daily dosing. KP415 utilizes KemPharm’s LAT platform technology to
potentially enable abuse-deterrent properties at the molecular level which addresses the need for methylphenidate products with
abuse deterrent features on the market.
In addition, on July 14, 2016, KemPharm announced the completion of an End-of-Phase 1 (EOP1) review for KP201/IR, KemPharm’s
single-entity, benzhydrocodone HCl immediate-release product candidate designed for the treatment of acute pain. KemPharm
believes that KP201/IR may also have abuse deterrent properties. KemPharm requested an EOP1 review for KP201/IR ahead of an
anticipated IND submission based on the amount of data, both nonclinical and clinical, generated from the development of
Apadaz. As previously reported, data from KemPharm’s intranasal human abuse liability trial (KP201.A03), which compared
hydrocodone exposure following insufflation of benzhydrocodone HCl (KP201) vs. hydrocodone bitartrate (HB), demonstrated a
statistically significant reduction in Cmax, a delay in Tmax, and a significant decrease in total exposure to
hydrocodone, especially at early time points typically associated with increased drug liking, abuse and safety. Secondary
endpoints related to drug liking, including drug liking Emax, pupillometry and ease of snorting also showed significant
differences between KP201 and HB, with KP201 demonstrating lower drug liking, less pupil dilation and higher difficulty of snorting
than HB. KemPharm remains encouraged by these findings and anticipates filing an IND for KP201/IR before the end of 2016.
Q2 2016 Financial Results:
KemPharm’s reported net income of $9.8 million, or $0.59 net income per basic share, and ($0.58) net loss per
diluted share for the quarter ended June 30, 2016, compared to a net loss of ($29.7) million, or ($2.45) net loss per basic and
diluted share, for the same period in 2015. Net income for the quarter ended June 30, 2016, was driven primarily by a $20.8 million
decrease in the fair value of KemPharm’s derivative and warrant liability as of June 30, 2016. Loss from operations for the
quarter ended June 30, 2016, was $9.3 million, compared to $6.0 million for the same period in 2015. The increase in loss
from operations period-to-period was primarily due to a $2.2 million increase in research and development expenses primarily
related to activity for KP511 and KP415, and an increase in general and administrative costs of $1.1 million, primarily due to an
increase in headcount and commercial activities.
As of June 30, 2016, the total of cash and cash equivalents, restricted cash, marketable securities and long-term investments
was $102.6 million, and was a decrease of $8.4 million compared to March 31, 2016.
Conference Call Information:
The Company will host a conference call and live audio webcast on Wednesday, August 10, 2016, at 8:30 a.m. ET, to discuss its
corporate and financial results for the second quarter 2016. Interested participants and investors may access the conference call
by dialing either:
- (866) 395-2480 (U.S.)
- (678) 509-7538 (international)
- Conference ID: 56389138
An audio webcast will be accessible via the Investor Relations section of the KemPharm website http://investors.kempharm.com/. An archive of the webcast will remain available for 90
days beginning at approximately 9:30 a.m. ET, on August 10, 2016.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs
to treat serious medical conditions through its LAT platform technology. KemPharm utilizes its LAT platform technology to
generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other CNS disorders.
Caution Concerning Forward Looking Statements
This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking
statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of
words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or
the negative versions of those words or other comparable words. These forward-looking statements include statements regarding the
outcome of the regulatory approval process for Apadaz, the expected features and characteristics of KP201/IR, KP511/ER and KP415,
the expected timing of filing of INDs for KP201/IR and KP415, and potential submissions of NDAs for KP201/IR, KP511/ER and
KP415. These forward-looking statements are not guarantees of future actions or performance. These forward-looking statements
are based on information currently available to KemPharm and its current plans or expectations, and are subject to a number of
uncertainties and risks that could significantly affect current plans. Actual results and performance could differ materially from
those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and
uncertainties associated with: KemPharm's financial resources and whether they will be sufficient to meet KemPharm's business
objectives and operational requirements; results of earlier studies and trials may not be predictive of future clinical trial
results; the protection and market exclusivity provided by KemPharm's intellectual property; risks related to the drug discovery
and the regulatory approval process; the impact of competitive products and technological changes; and the FDA approval process
under the Section 505(b)(2) regulatory pathway, including without limitation any timelines for related approval. KemPharm's
forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially
from those expressed or implied by such forward-looking statements. These and other risks concerning KemPharm’s business are
described in additional detail in KemPharm's Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, and KemPharm’s
other Periodic and Current Reports filed with the Securities and Exchange Commission. KemPharm is under no obligation to (and
expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information,
future events or otherwise.
KEMPHARM, INC.
UNAUDITED CONDENSED STATEMENTS OF OPERATIONS
(In Thousands, Except Share and Per Share Amounts) |
| |
| |
|
Three months ended June 30, |
|
Six months ended June 30, |
| |
|
2016 |
|
2015 |
|
2016 |
|
2015 |
| Revenue |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
| Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Research and development |
|
|
4,988 |
|
|
|
2,768 |
|
|
|
8,222 |
|
|
|
4,887 |
|
| General and administrative |
|
|
4,287 |
|
|
|
3,188 |
|
|
|
8,023 |
|
|
|
4,165 |
|
| Total operating expenses |
|
|
9,275 |
|
|
|
5,956 |
|
|
|
16,245 |
|
|
|
9,052 |
|
| Loss from operations |
|
|
(9,275 |
) |
|
|
(5,956 |
) |
|
|
(16,245 |
) |
|
|
(9,052 |
) |
| Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss on extinguishment of debt |
|
|
— |
|
|
|
— |
|
|
|
(4,740 |
) |
|
|
— |
|
| Interest expense related to amortization of debt issuance costs and discount |
|
|
(393 |
) |
|
|
(477 |
) |
|
|
(835 |
) |
|
|
(954 |
) |
| Interest expense on principal |
|
|
(1,475 |
) |
|
|
(654 |
) |
|
|
(2,625 |
) |
|
|
(1,286 |
) |
| Fair value adjustment |
|
|
20,763 |
|
|
|
(22,661 |
) |
|
|
31,041 |
|
|
|
(24,423 |
) |
| Interest and other income |
|
|
144 |
|
|
|
5 |
|
|
|
246 |
|
|
|
6 |
|
| Total other income (expense) |
|
|
19,039 |
|
|
|
(23,787 |
) |
|
|
23,087 |
|
|
|
(26,657 |
) |
| Income (loss) before income taxes |
|
|
9,764 |
|
|
|
(29,743 |
) |
|
|
6,842 |
|
|
|
(35,709 |
) |
| Income tax benefit (expense) |
|
|
4 |
|
|
|
— |
|
|
|
(8 |
) |
|
|
(7 |
) |
| Net income (loss) |
|
$ |
9,768 |
|
|
$ |
(29,743 |
) |
|
$ |
6,834 |
|
|
$ |
(35,716 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net income (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Basic |
|
$ |
0.59 |
|
|
$ |
(2.45 |
) |
|
$ |
0.41 |
|
|
$ |
(4.91 |
) |
| Diluted |
|
$ |
(0.58 |
) |
|
$ |
(2.45 |
) |
|
$ |
(1.36 |
) |
|
$ |
(4.91 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Weighted average common shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Basic |
|
|
14,597,449 |
|
|
|
12,157,514 |
|
|
|
14,546,576 |
|
|
|
7,272,326 |
|
| Diluted |
|
|
15,435,322 |
|
|
|
12,157,514 |
|
|
|
15,583,390 |
|
|
|
7,272,326 |
|
KEMPHARM, INC.
CONDENSED BALANCE SHEETS
(In Thousands, Except Share and Par Value Amounts) |
| |
| |
|
As of
June 30, |
|
As of
December 31, |
| |
|
2016 |
|
2015 |
| |
|
(unaudited) |
|
|
|
|
| Assets |
|
|
|
|
|
|
|
|
| Current assets: |
|
|
|
|
|
|
|
|
| Cash and cash equivalents |
|
$ |
27,510 |
|
|
$ |
32,318 |
|
| Restricted cash |
|
|
1,100 |
|
|
|
— |
|
| Marketable securities |
|
|
55,134 |
|
|
|
19,002 |
|
| Prepaid expenses and other current assets |
|
|
824 |
|
|
|
2,758 |
|
| Total current assets |
|
|
84,568 |
|
|
|
54,078 |
|
| Property and equipment, net |
|
|
1,105 |
|
|
|
403 |
|
| Long-term investments |
|
|
18,850 |
|
|
|
— |
|
| Other long-term assets |
|
|
111 |
|
|
|
109 |
|
| Total assets |
|
$ |
104,634 |
|
|
$ |
54,590 |
|
| |
|
|
|
|
|
|
|
|
| Liabilities and stockholders' equity (deficit) |
|
|
|
|
|
|
|
|
| Current liabilities: |
|
|
|
|
|
|
|
|
| Accounts payable and accrued expenses |
|
$ |
5,356 |
|
|
$ |
4,906 |
|
| Current portion of convertible notes |
|
|
1,932 |
|
|
|
1,369 |
|
| Current portion of term notes |
|
|
— |
|
|
|
2,041 |
|
| Current portion of capital lease obligation |
|
|
103 |
|
|
|
26 |
|
| Total current liabilities |
|
|
7,391 |
|
|
|
8,342 |
|
| Convertible notes, net |
|
|
90,389 |
|
|
|
7,412 |
|
| Term notes, net |
|
|
— |
|
|
|
11,118 |
|
| Derivative and warrant liability |
|
|
6,043 |
|
|
|
37,839 |
|
| Other long-term liabilities |
|
|
478 |
|
|
|
— |
|
| Total liabilities |
|
|
104,301 |
|
|
|
64,711 |
|
| |
|
|
|
|
|
|
|
|
| Commitments and contingencies (Note D) |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
| Stockholders' deficit: |
|
|
|
|
|
|
|
|
| Common stock, $0.0001 par value, 250,000,000 shares authorized, 14,646,982 shares issued and
outstanding as of June 30, 2016 (unaudited); 14,490,954 shares issued and outstanding as of December 31, 2015 |
|
|
1 |
|
|
|
1 |
|
| Additional paid-in capital |
|
|
98,322 |
|
|
|
94,702 |
|
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued or
outstanding as of June 30, 2016 (unaudited) or December 31, 2015 |
|
|
— |
|
|
|
— |
|
| Accumulated deficit |
|
|
(97,990 |
) |
|
|
(104,824 |
) |
| Total stockholders' equity (deficit) |
|
|
333 |
|
|
|
(10,121 |
) |
| Total liabilities and stockholders' equity (deficit) |
|
$ |
104,634 |
|
|
$ |
54,590 |
|
| |
|
|
|
|
|
|
|
|
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 jrando@tiberend.com jdrumm@tiberend.com Media Contact: Daniel L. Cohen Executive VP, Government and Public Relations KemPharm, Inc. 202-329-1825 dcohen@kempharm.com
